Clinical trials: Metastases, CNS
Parkinson Disease
Motor Control During Rapid Eye Movement (REM) Sleep Behaviour Disorder
To compare the electrical activity of SubThalamic Nuclei (STN), by mean of local field potentials recordings, during the phasic behaviours of RBD with the electrical activity recorded at this level during the execution of…
- Trial name
- RevesParkNST (NCT01886131)
- Testing
- Synchronised video-polysomnography
- Where
- 2 sites in France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Toulouse
Neuroblastoma, CNS Metastases
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to…
- Conditions
- Neuroblastoma, CNS Metastases, Leptomeningeal Metastases
- Trial name
- NCT03275402
- Testing
- 131I-omburtamab
- Where
- 8 sites in United States, Denmark and 2 more
- Volunteers
- 52 people
- Sponsor
- Y-mAbs Therapeutics
Brain Metastases
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)
- Trial name
- NCT03075072
- Testing
- Whole brain radiation, Stereotactic radiation (SRS)
- Where
- 2 sites in United States
- Volunteers
- 196 people
- Sponsor
- Brigham and Women's Hospital
Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
This study was an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
- Trial name
- NCT04940065
- Testing
- Kesimpta
- Where
- 103 sites in Japan
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
This is a phase II, randomized, multicenter, open-label study designed to assess the safety and tolerability of concomitant chemotherapy with low-dose temozolomide during whole brain radiation and later on at 14 days on/14 days…
- Trial name
- NCT00266812
- Testing
- Temozolomide and radiotherapy, Whole brain radiotherapy
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
HER2-positive Advanced Breast Cancer, Brain Metastases
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
A total of 224 subjects of HER2-positive advanced breast cancer with brain metastases are planned to be enrolled. Eligible subjects will be randomly assigned in a 1:1 ratio to the group receiving Trastuzumab Rezetecan combined…
- Conditions
- HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy
- Trial name
- NCT07100600
- Testing
- Trastuzumab Rezetecan, FSRT or WBRT
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Henan Cancer Hospital
Post-Traumatic Headache
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
This study will evaluate the effectiveness of Treximet when taken for post traumatic headache by measuring any change in the number of headache days or any change in a subject's ability to think following treatment with study…
- Trial name
- NCT01053507
- Testing
- sumatriptan/naproxen sodium
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cady, Roger, M.D.
Breast Cancer
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
CONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational, orally administered taxane, in patients with metastatic breast cancer (MBC).
- Trial name
- CONTESSA TRIO (NCT03952325)
- Testing
- Tesetaxel, Nivolumab, Pembrolizumab
- Where
- 12 sites in United States, Singapore and 1 more
- Volunteers
- 294 people
- Sponsor
- Odonate Therapeutics, Inc.
Stroke, Acute
Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic
TELEstroke to CAre for STroke Patients at a Comprehensive Stroke Center (TELECAST-CSC) during the COVID-19 pandemic is a pre-post study evaluating guideline-based acute ischemic stroke care following the implementation of…
- Trial name
- TELECAST-CSC (NCT04761874)
- Testing
- Telestroke
- Where
- United States
- Volunteers
- 296 people
- Sponsor
- University of Minnesota
Friedreich Ataxia, Cardiomyopathy, Secondary
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).
- Trial name
- SUNRISE-FA 2 (NCT07721025)
- Testing
- LX2006, Usual Care
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Lexeo Therapeutics
Post-Dural Puncture Headache
Sphenopalatine Block or Epidural Bloodpatch for Post Dural Puncture Headache: Randomized Controlled Trial
Introduction: Recently sphenopalatine block emerged as an alternative to epidural blood patch for post dural puncture headache but the investigators do not know if it has significant efficacy when compared to epidural blood…
- Trial name
- NCT02984618
- Testing
- Sphenopalatine ganglion block, Epidural blood patch
- Where
- Brazil
- Volunteers
- 19 people
- Sponsor
- Brasilia University Hospital
Ischemic Stroke, Transient Ischemic Attack
Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke
This is a randomized, controlled, active comparator arm, outcome assessor blind, parallel group design on 90 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is assess the…
- Trial name
- TACAMINIS (NCT04738097)
- Testing
- Ticagrelor 90mg, Clopidogrel 75 mg
- Where
- 2 sites in Iran
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Mazandaran University of Medical Sciences
Brain Metastases
Frameless Stereotactic Radiosurgery for Brain Metastases
The investigators plan to study high dose, single treatment radiation, using a plastic mask instead of a head frame that pins into a patient's skull.
- Trial name
- NCT01476878
- Testing
- Frameless Stereotactic Radiosurgery with radiation mask
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Alberta Health services
Postdural Puncture Headache
2 Dose Neuraxial Morphine for Prevention of PDPH
Neuraxial analgesia (most commonly continuous epidural or combined spinal epidural) is the most effective modality available for pain relief during labor.
- Trial name
- NCT02473276
- Testing
- Morphine, Sterile normal saline
- Where
- 4 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Columbia University
Metastatic Malignant Neoplasm in the Brain
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
This phase I trial studies the side effects and best dose of trametinib with or without whole brain radiation therapy in treating patients with brain metastases.
- Trial name
- NCT02015117
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Metformin Treatment in Progressive Multiple Sclerosis
The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis
- Trial name
- NCT05349474
- Testing
- Metformin 500 Mg Oral Tablet, up to 4 tablets a day
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, Los Angeles
Chronic Myeloproliferative Disorders, Leukemia
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003082
- Testing
- monoclonal antibody A27.15, monoclonal antibody E2.3
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Arizona
Brain Metastases, Breast Cancer
STAR Cape+BKM120 MBC With Brain Met
This is a study to determine the safety and effectiveness of BKM120 plus capecitabine in breast cancer patients with brain metastases. Both capecitabine and BMK120 have previously shown activity in patients with breast cancer.
- Conditions
- Brain Metastases, Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT02000882
- Testing
- BKM120, capecitabine, Trastuzumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- US Oncology Research
Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
This phase I trial investigates the side effects and best dose of adavosertib and how well it works when given in combination with radiation therapy in treating patients with esophageal or gastroesophageal junction cancer for…
- Conditions
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04460937
- Testing
- Adavosertib, Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
HER2-positive, Metastatic Breast Cancer
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
A Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose Disease is resistant or refractory to Tyrosine kinase inhibitors (TKI).
- Trial name
- NCT05018702
- Testing
- ARX788
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.